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Abstract
Background: Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from
those of early breast cancer. The purpose of this study was to identify the clinical significance of potential predictive and
prognostic factors in breast cancer patients treated by neoadjuvant chemotherapy.
Methods:  A total of 145 stage II and III breast cancer patients received neoadjuvant docetaxel/doxorubicin
chemotherapy were enrolled in this study. We examined the clinical and biological factors (ER, PR, p53, c-erbB2, bcl-2,
and Ki-67) by immunohistochemistry. We analyzed clinical outcome and their correlation with clinicopathologic
parameters.
Results: Among the clinicopathologic parameters investigated, none of the marker was correlated with response rate
(RR) except triple negative phenotype. Patients with triple negative phenotype showed higher RR (83.0% in triple negative
vs. 62.2% in non-triple negative, p = 0.012) and pathologic complete RR (17.0% in triple negative vs. 3.1% in non-triple
negative, p = 0.005). However, relapse free survival (RFS) and overall survival (OS) were significantly shorter in triple
negative breast cancer patients (p < 0.001, p = 0.021, respectively). Low histologic grade, positive hormone receptors,
positive bcl-2 and low level of Ki-67 were associated with prolonged RFS. In addition, positive ER and positive bcl-2 were
associated with prolonged OS. In our homogeneous patient population, initial clinical stage reflects RFS and OS more
precisely than pathologic stage. In multivariate analysis, initial clinical stage was the only significant independent prognostic
factor to impact on OS (hazard ratio 3.597, p = 0.044).
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Conclusion: Several molecular markers provided useful predictive and prognostic information in stage II and III breast
cancer patients treated with neoadjuvant docetaxel/doxorubicin chemotherapy. Triple negative phenotype was
associated with shorter survival, even though it was associated with a higher response rate to neoadjuvant chemotherapy.
Background
Neoadjuvant chemotherapy has become a standard ther-
apy for patients with locally advanced breast cancer [1,2].
Major roles of neoadjuvant chemotherapy are 1) conver-
sion of inoperable or inflammatory breast cancer to oper-
able status 2) increasing the rate of breast conserving
surgery, and 3) individual in vivo chemosensitivity test of
the tumor [2-4]. However, a potential disadvantage of
neoadjuvant chemotherapy is the loss of prognostic value
provided by tumor size and nodal status at surgery and
before adjuvant chemotherapy [3,4].
A number of studies have investigated prognostic factors
in the neoadjuvant setting. At present, pathologic com-
plete response (pCR) is a useful independent prognostic
factor and the patients who achieved pCR showed better
survival compared with those with residual tumor [5-8].
However a small percentage of patients achieved pCR, and
a significant portion of patients with pCR had recurrent
disease [9]. Molecular markers such as estrogen receptor
(ER), progesterone receptor (PR), p53, Ki-67 and c-erbB2
considered predictive or prognostic factors in neoadju-
vant setting [7,10-14]. However, these markers are often
contradictory and not conclusive because of heterogene-
ous patient populations, small sample sizes, and different
chemotherapeutic regimens. Due to alterations in molec-
ular mechanism during neoadjuvant chemotherapy, and
also uncertainty regarding the prognostic value of clinico-
patholgic parameters, physicians felt difficulties to accu-
rately define risk profiles and identify optimal post
operation treatment including chemotherapy and radia-
tion therapy.
We ourselves have conducted neoadjuvant docetaxel/dox-
orubicin combination chemotherapy in stage II and III
breast cancer patients. The purpose of this study was to
identify the clinical significance of potential predictive
and prognostic factors in the neoadjuvant setting.
Methods
Patients and treatment
From March 2002 to March 2006, patients were enrolled
in this study. Eligibility criteria included: 1) pathologi-
cally confirmed breast cancer by core needle biopsy, 2)
clinical stage II or III, 3) objective measurable lesion, 4)
ECOG performance 0–2, 5) previously untreated, 6) ade-
quate bone marrow, hepatic, cardiac, and renal functions.
Initial evaluation included clinical examination, mam-
mography, breast ultrasonography, computed tomogra-
phy of chest, bone scan, and breast magnetic resonance
imaging (MRI). Initial tumor size was measured by MRI.
Initial nodal staging was evaluated by physical examina-
tion and by computed tomography. After three cycles of
neoadjuvant chemotherapy, the patients were re-evalu-
ated for response.
The chemotherapeutic regimen comprised docetaxel (75
mg/m2 or 60 mg/m2) and doxorubicin (60 mg/m2 or 50
mg/m2) by intravenous infusion every three weeks for
three cycles, with granulocyte colony stimulating factor as
primary prophylaxis. After completion of neoadjuvant
treatment, the patients underwent primary surgery and
received three more cycles of docetaxel and doxorubicin
as adjuvant chemotherapy, followed by radiation or hor-
monal therapy if indicated [15]. If the patients had been
found to have progressive disease, they underwent pri-
mary surgery and received adjuvant chemotherapy using
different regimens. This regimen was known to be effec-
tive and well tolerated as neoadjuvant chemotherapy for
stage II or III breast cancer [16].
Radiologic response was evaluated using breast MRI for
primary breast cancer measurement and chest CT for
lymph node measurement by RECIST criteria [17] as fol-
lows; complete response was defined as the complete dis-
appearance of all assessable lesions; partial response as a
>30% reduction in the sum of the longest diameters of all
measurable lesions; stable disease as a <30% reduction or
a <20% increase in the sum of the longest diameters of all
measurable lesions; and progressive disease was defined
as >20% increase in the area(s) of original measurable
lesion or the appearance of a new lesion.
We examined the conventional clinicopathologic factors
including the six different biological factors (ER, PR, p53,
c-erbB2, bcl-2, and Ki-67) by immunohistochemistry and
evaluated their association with clinical outcomes. The
study protocol was reviewed and approved by the institu-
tional review board at the Seoul National University Hos-
pital. Recommendations of the Declaration of Helsinki
for biomedical research involving human subjects were
also followed.
Pathologic Examination and Immunohistochemistry
The pretreatment formalin-fixed, paraffin-embedded tis-
sue blocks were used for immunohistochemistry. The
pathological tumor stage assessed according to the criteria
established by the 6th edition of AJCC cancer stagingBMC Cancer 2007, 7:203 http://www.biomedcentral.com/1471-2407/7/203
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manual [18], the grade of the tumor according to the
Scarff-Bloom-Richardson classification modified by
Elston and Ellis [19]. The pathologic complete response
(pCR) was defined as complete disappearance of invasive
carcinoma in both breast and axillary lymph nodes after
three cycles of chemotherapy. Residual ductal carcinoma
in-situ was included in the pCR category.
ER, PR, c-erbB2, p53, bcl-2, and Ki-67 expressions were
evaluated by the avidin-biotin complex immunohisto-
chemical technique [20]. Tissue sections (4-μm thickness)
from paraffin-embedded tissue blocks were cut, deparaffi-
nized in xylene, rehydrated with graded ethanol, and
immersed in Tris-buffered saline. After an antigen-
retrieval process, primary antibodies were used as previ-
ously described [21]. The companies that supplied the pri-
mary antibodies and the dilution factors used were; ER
(Dako Corporation, Carpinteria, CA, USA; 1:50), PR
(Dako Corporation; 1:50), c-erbB2 (Novocastra Laborato-
ries Ltd., New Castle-Upon-Tyne, U.K.; 1:200), p53 (Dako
Corporation; 1:1200), bcl-2 (Dako Corporation; 1:50),
and Ki-67 (Dako Corporation; 1:800). All primary anti-
bodies were mouse monoclonal antibodies. Biotinylated
anti-mouse antibody was used as secondary antibody and
streptavidin horseradish peroxidase (Zymed laboratories,
San Francisco, CA, USA) methods were used.
A cut-off value of 10% or more positively stained nuclei in
ten high-power fields was used to define ER and PR posi-
tivity. C-erbB2 scores of 0, 1 and 2 were considered nega-
tive, and a score of 3 was considered positive [22]. In the
current study, we did not have FISH information available
on the majority of c-erbB2 positive patients. Ki-67 with ≤
5% and p53 with <25% were considered as low expres-
sion. Triple negative subtype was defined as ER negative,
PR negative, and c-erbB2 negative, regardless of the
expression of EGFR or basal cytokeratins.
Statistical analysis
The significance of the difference in the response rate
among different groups was calculated using the Chi-
squared test and Fisher's exact test, where appropriate.
Multivariate analyses were carried out using the Cox pro-
portional hazard regression models. Relapse free survival
(RFS) was determined as the interval between the initia-
tion of neoadjuvant chemotherapy and the date when dis-
ease relapse or progression was first documented or the
date of death from any cause. Overall survival (OS) was
measured from the date of neoadjuvant chemotherapy
initiation to the date of death. Survival comparisons
between different groups were made using the log-rank
tests. All values were two sided and statistical significance
was defined as p < 0.05. SPSS version 12.0 software (SPSS,
Inc., Chicago, IL, USA) was used for all statistical analyses.
Results
Patient Characteristics and efficacy
A total of 145 patients with a median age of 45 (range 25–
69) were evaluated in this study. The clinical characteris-
tics of the patients are summarized in Table 1. Most of the
patients (84.1%) were clinical stage III at the time of ini-
tial diagnosis and eighteen patients (12.4%) had inflam-
matory breast cancers. The median tumor size was 5 cm
which is relatively large for Asian woman who have small
breast. The breast conserving surgery rate was 35.9%. The
overall radiologic response rate (RR) was 68.9% including
7 complete response (4.8%) and 93 partial response
(64.1%) (Table 2). All 7 radiologic complete responder
showed pCR and four patients who showed radiologic
residual lesion were turned out to pCR. Consequently,
eleven patients (7.6%) achieved a pCR (Table 2).
Of 145 patients, 138 patients including patients with pCR
received three more cycles of docetaxel and doxorubicin
as planned adjuvant chemotherapy. Three patients who
showed progressive disease and 4 patients who were unac-
ceptable to docetaxel received different adjuvant chemo-
therapy using FAC (5-fluorouracil, doxorubicin,
cyclophosphamide), AC (doxorubicin, cyclophospha-
mide) or CMF (cyclophosphamide, methotrexate, 5-fluor-
ouracil) after curative surgery.
Median follow-up duration was 18.6 months. Estimated
one and three year relapse free survival rates were 88.7%
and 56.5%, respectively. Estimated one and three year
overall survival rates were 97.5% and 71.6% respectively.
Correlation between clinicopathological variables and 
response rate
Potential traditional predictive factors (age, performance,
stage, nuclear grade, histologic grade, ER, PR, p53, c-
erbB2, bcl-2 and Ki-67) were analyzed. Table 3 compares
radiologic RR and predictive factors. pCR was correlated
with radiologic RR (p = 0.018). pCR and radiologic RR
according to ER/PR/c-erbB2 are summarized in Table 4.
Patients with triple negative breast cancer showed higher
RR (83.0% in triple negative vs. 62.2% in non-triple nega-
tive, p = 0.012).
Correlation between clinicopathological variables and 
survival
The results of univariate analyses for RFS and OS were
shown in Table 5. Responding to neoadjuvant chemother-
apy did not affect RFS or OS. Among the parameters inves-
tigated, low histologic grade, positive ER, positive PR,
positive bcl-2 and low level of Ki-67 were associated with
prolonged RFS in univariate analysis. In addition, positive
ER and positive bcl-2 were associated with prolonged
overall survival (OS) in univariate analysis. In terms of
stage, initial clinical stage reflects RFS and OS more pre-BMC Cancer 2007, 7:203 http://www.biomedcentral.com/1471-2407/7/203
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cisely than pathologic stage. Kaplan-Meier plots (Figure 1)
show the survival curve according to clinical and patho-
logic stage.
We also performed multivariate analysis (Table 6). Cox
proportional hazard regression analysis for OS included
statistically significant variables (initial clinical stage, ER,
bcl-2, and triple negative). In multivariate analysis, initial
clinical stage was the only significant independent prog-
nostic factor to impact on OS (hazard ratio 3.597, p =
0.044).
Clinical significance of triple negative breast cancer
Forty seven patients (32.4%) of the 145 were triple nega-
tive breast cancer. Clinicopathologic variables according
to triple negative are summarized in Table 7. Triple nega-
tive breast cancer patients showed statistically higher
nuclear grade, and lower bcl-2 positive rate than non-tri-
ple negative breast cancer patients. A trend for high levels
of Ki-67 was also observed in triple negative, although it
did not reach statistical significance (p = 0.053). The pCR
rate and clinical RR in triple negative were significantly
higher (p = 0.005, p = 0.012, respectively). However, RFS
and OS were significantly short in triple negative breast
cancer patients (p < 0.001, p = 0.021, respectively). RFS
and OS survival curves for triple negative and non-triple
negative are shown in Figure 2. Because c-erbB2 positivity
by immunohistochemistry was unclear, we conducted a
second analysis considering 2+ as c-erbB2 positive. Using
this definition of triple negative, the results were similar.
Discussion
The clinical course of breast cancer patients treated with
neoadjuvant chemotherapy remains difficult to predict,
because histologically homogeneous breast cancers vary
in response to therapy and have divergent outcomes [23].
Table 1: Clinical characteristics of 145 patients
Characteristics No. of Pt (%)
Median age (range) 45 (range 25–69)
Age < 50 102 (70.3)
Age ≥ 50 43 (29.7)
Performance status
ECOG 0–1 139 (95.9)
ECOG 2 6 (4.1)
Pathologic characteristics
Invasive ductal carcinoma 137 (94.5)
Others 8 (5.5)
Initial clinical stage
IIA 2 (1.4)
IIB 21 (14.5)
IIIA 70 (48.3)
IIIB 34 (23.4)
IIIC 18 (12.4)
Median tumor size 5.0 cm (range 1.2–12.0 cm)
Inflammatory breast cancer
Yes 18 (12.4)
No 127 (87.6)
Type of surgery
Breast conserving 52 (35.9)
Mastectomy 93 (64.1)
Adjuvant hormonal therapy
Yes 63 (43.4)
No 82 (56.6)
Radiation therapy
Yes 128 (88.3)
No 17 (11.7)
ECOG, Eastern Cooperative Oncology Group.
Table 2: Radiologic and pathologic response after docetaxel plus 
doxorubicin neoadjuvant chemotherapy
Response No. of Pts (%)
Radiologic response
Complete response 7 (4.8)
Partial response 93 (64.1)
Stable disease 42 (29.0)
Progressive disease 3 (2.1)
Pathologic complete response
Yes 11 (7.6)
No 134 (92.4)BMC Cancer 2007, 7:203 http://www.biomedcentral.com/1471-2407/7/203
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As a result, many researchers have tried to identify prog-
nostic factors in order to give optimal individualized ther-
apy in locally advanced breast cancer, as well as in early
breast cancer. Currently, pCR is the most powerful prog-
nostic factor for prolonged survival in neoadjuvant chem-
otherapy [3,5,6,24]. However, a significant proportion of
patients with pCR have recurrent diseases [9]. Moreover,
the prognostic factors for patients receiving neoadjuvant
chemotherapy differ from those for patients who receive
adjuvant or palliative chemotherapy, because pathologic
parameters including tumor size and nodal status are
changed by neoadjuvant chemotherapy [3]. Hence we
tried to determine the additional predictive and prognos-
tic markers for early relapse other than pCR in neoadju-
vant setting.
Table 4: Pathologic complete response and radiologic response rate according to ER/PR/c-erbB2
No. of Pts pCR (N = 11) p-value Radiologic Response (RR %) p-value
Variables No. of Pts (%) No. of Pts (%)
ER Positive 64 1 (1.6) 0.023 41 (64.1) 0.257
Negative 81 10 (12.3) 59 (72.8)
PR Positive 44 1 (2.3) 0.173 28 (63.6) 0.360
Negative 101 10 (9.9) 72 (71.3)
c-erbB2 0/+/++ 107 9 (8.4) 0.728 76 (71.0) 0.368
+++ 38 2 (5.3) 24 (63.2)
Table 3: Correlation between clinicopathological variables and radiologic response rate
Variables No. of Pts Responders (RR %) p-value*
Age < 50
≥ 50
102
43
69 (67.6)
31 (72.1)
0.597
Performance ECOG 0–1
ECOG 2
139
6
95 (68.3)
5 (83.3)
0.666
Initial clinical stage IIA, IIB, IIIA
IIIB, IIIC
93
52
64 (68.8)
36 (69.2)
0.959
pCR No 134 89 (66.4) 0.018
Yes 11 11 (100.0)
Nuclear grade I, II 41 22 (53.7) 0.069
III 87 61 (70.1)
Unknown 17 -
Histologic grade I, II 39 24 (61.5) 0.741
III 82 53 (64.6)
Unknown 24 -
ER Positive 64 41 (64.1) 0.257
Negative 81 59 (72.8)
PR Positive 44 28 (63.6) 0.360
Negative 101 72 (71.3)
bcl-2 Positive 63 45 (71.4) 0.749
Negative 74 51 (68.9)
Unknown 8 -
Ki-67 Low expression# 56 34 (60.7) 0.066
High expression 85 64 (75.3)
Unknown 4 -
p53 Low expression# 67 43 (64.2) 0.219
High expression 76 56 (73.7)
Unknown 2 -
c-erbB2 0/+/++ 107 76 (71.0) 0.368
+++ 38 24 (63.2)
Triple negative No 98 61 (62.2) 0.012
Yes 47 39 (83.0)
RR, response rate; pCR, pathologic complete response; ER, estrogen receptor; PR, progesterone receptor.
*based on Pearson's χ2 test (using Fisher's exact test if N ≤ 5).
#Ki-67 with ≤ 5% and p53 with <25% were considered as low expression.BMC Cancer 2007, 7:203 http://www.biomedcentral.com/1471-2407/7/203
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In the present study, we found that a triple negative phe-
notype was a predictive marker for response in neoadju-
vant docetaxel and doxorubicin chemotherapy. In
addition, initial clinical stage, hormone receptor, histo-
logic grade, bcl-2 and Ki-67 were all associated with RFS.
In other published studies using non-anthracycline based
chemoendocrine agents [11], it was reported that positive
ER, absence of c-erbB2 and decrease in Ki-67 were associ-
ated with a good clinical response. Overexpression of p53
was also reported to be associated with a lower response
rate to anthracycline based neoadjuvant chemotherapy
[13,14,25] and to be an independent factor for poor sur-
vival [14,25]. In our results, overexpression of p53 failed
to show clinical significance in neoadjuvant setting. How-
ever, p53 mutation which was associated with response to
neoadjuvant chemotherapy [13] was not in agreement
with p53 overexpression measured by quantitative immu-
nohistochemistry. Additional mutational study of p53 is
needed to clarify correlation between p53 and clinical
outcomes. The predictive or prognostic value of bcl-2,
apoptosis regulatory protein, remains controversial in
neoadjuvant setting. In one study, higher bcl-2 expression
was predictive for pCR [26], while other studies did not
find any correlation between bcl-2 expression and clinical
response [25,27]. Traditional prognostic makers such as
nodal stage [28] and c-erbB2 [10,11] showed no prognos-
tic value in our result. Relatively short follow up period of
18.6 months might partially explain this. As yet, these bio-
logic markers are inconclusive, owing to heterogeneous
chemotherapeutic regimens and the small sample size of
extant studies. More studies should be carried out, to iden-
tify more precisely the prognostic markers in the neoadju-
vant setting.
In our results, pCR which is considered to be the most
powerful prognostic factor did not show significant prog-
nostic value. Possible explanations for the weakened
prognostic power of pCR are the relatively lower rate of
pCR (7.6%), the short course of neoadjuvant chemother-
apy, and the short duration of follow up (18.6 months).
Kaplan-Meier analyses of survival according to clinical and pathologic stages Figure 1
Kaplan-Meier analyses of survival according to clinical and pathologic stages.BMC Cancer 2007, 7:203 http://www.biomedcentral.com/1471-2407/7/203
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We conducted only three cycles of neoadjuvant chemo-
therapy, while other neoadjuvant regimens have been
based on four to six cycles, and have shown higher pCR
rates (8–26%) than our own study [24,29,30].
Optimal treatment after neoadjuvant chemotherapy
remains still uncertain [31]. Unlike early breast cancer, it
is not yet clear whether adjuvant therapy should be con-
ducted according to initial clinical stage or post operative
pathologic stage. In our homogeneous patient popula-
tion, initial clinical stage was an independent prognostic
factor for survival, while pathologic stage failed to reflect
ultimate survival. This result was obtained by using accu-
rate staging work up modalities, including breast MRI and
chest computed tomography. In contrast, Carey et al [32]
analyzed 135 patients with median follow up of 5 years
and reported that pathologic stage after neoadjuvant
chemotherapy was useful for predicting survival. Chollet
et al [33] also reported prognostic value of residual tumor
size and nodal status after neoadjuvant chemotherapy
with median follow up of 9.3 year. However, despite short
duration of follow up, our results showed statistical supe-
riority of initial clinical stage in predicting survival. This
result might give us useful information when determining
post operative adjuvant therapy.
Triple negative breast cancer has been reported as being
associated with a poor clinical outcome in early breast
cancer [34,35]. In locally advanced breast cancer, there are
limited data about response to chemotherapy and sur-
vival. In the present study, we found that triple negative
breast cancer responded to neoadjuvant chemotherapy
Table 5: Correlation between clinicopathological variables and survival-univariate analysis
RFS OS
Variables No. of Pt HR* (95% CI) p-value HR* (95% CI) p-value
Age <50 102 1 0.317 1 0.283
≥50 43 1.476 (0.688–3.166) 1.831 (0.606–5.533)
Performance ECOG 0–1 139 1 0.686 1 0.888
ECOG 2 6 1.349 (0.316–5.756) 1.160 (0.148–9.073)
Initial clinical stage IIA, IIB, IIIA 93 1 0.017 1 0.010
IIIB, IIIC 52 2.370 (1.116–4.815) 4.764 (1.462–15.525)
pCR No 134 1 0.817 NA# NA#
Yes 11 1.186 (0.281–5.005)
Pathologic stage pCR~IIIA 113 1 0.288 1 0.086
IIIB, IIIC 32 1.525 (0.700–3.319) 2.608 (0.874–7.786)
Pathologic N stage N0 42 1 0.636 1 0.566
N1–3 103 0.828 (0.378–1.812) 1.558 (0.342–7.099)
Radiologic response Responder 100 1 0.515 1 0.683
Non-responder 45 0.776 (0.361–1.665) 1.258 (0.419–3.775)
Nuclear grade I, II 41 1 0.151 1 0.141
III 87 1.894 (0.792–4.532) 2.689 (0.722–10.023)
Histologic grade I, II 39 1 0.020 1 0.132
III 82 4.159 (1.248–13.865) 4.820 (0.621–32.387)
E R P o s i t i v e 6 4 10 . 0 0 110 . 0 2 8
Negative 81 5.410 (2.073–14.119) 9.921 (1.289–76.349)
P R P o s i t i v e 4 4 10 . 0 0 510 . 1 6 6
Negative 101 7.778 (1.851–32.673) 4.278 (0.547–33.476)
bcl-2 Positive 63 1 0.034 1 0.046
Negative 74 2.351 (1.068–5.175) 4.705 (1.030–21.490)
K i - 6 7 L o w  e x p r e s s i o n 5 6 10 . 0 3 810 . 0 8 2
High expression 85 2.357 (1.050–5.287) 3.263 (0.861–12.363)
p53 Low expression 67 1 0.869 1 0.670
High expression 76 1.063 (0.515–2.193) 1.281 (0.410–3.998)
c-erbB2 0/+/++ 107 1 0.242 1 0.678
+++ 38 1.555 (0.742–3.255) 1.273 (0.408–3.973)
Triple negative No 98 1 0.002 1 0.029
Yes 47 3.148 (1.539–6.441) 3.430 (1.133–10.378)
RFS, relapse free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
*Hazard ratio was calculated by Cox's proportional hazard model. If the hazard ratio is greater than 1, the hazard ratio can be thought of as the 
average increased risk of relapse or dying at any point in time compared with the reference group (described upper line).
#NA: Not available due to all censored in pCR.BMC Cancer 2007, 7:203 http://www.biomedcentral.com/1471-2407/7/203
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initially but then relapsed rapidly. Generally, tumor
responsiveness to chemotherapy is believed to be associ-
ated with a longer survival. However, in triple negative
phenotype, tumor responsiveness did not affect pro-
longed survival. In contrast, non-triple negative breast
cancer did not show a marked response but progressed
rather slowly. This paradoxical feature is consistent with
other studies conducted in basal-like breast cancer, which
was identified using gene expression profiling [36,37]. In
the present study, we did not conduct gene expression
profiling and hierachial cluster analysis. However, it is
known that 80–90% of triple negative breast cancers by
immunohistochemistry are basal-like subtypes by gene
expression profiling [35] and have a similar clinical
behavior, in addition [38,39]. It is notable that we were
able to obtain useful predictive and prognostic informa-
tion by simple immunohistochemistry without high cost.
It is not yet certain whether the poor prognosis of triple
negative breast cancer is due to its aggressive feature or
because of lack of targeted therapy, including adjuvant
hormonal therapy and c-erbB2 targeted agents. We
hypothesized that triple negative breast cancer itself seems
to reflect more aggressive tumor biology and growth rate
potential with high expression of Ki-67. Our data suggest
that patients with triple negative breast cancer should be
candidates for clinical trials to determine additional
agents including antiangiogenic agents.
Conclusion
Several molecular markers play a role as predictive and
prognostic factors in stage II and III breast cancer patients
receiving neoadjuvant chemotherapy. We also confirmed
the usefulness of initial clinical stage, as a predictor of sur-
vival. We found that triple negative phenotype was associ-
ated with shorter survival, even though it was associated
with a higher response rate to neoadjuvant chemotherapy.
These results might assist in identifying and understand-
ing the importance of clinically useful markers in the neo-
adjuvant setting, and help to optimize treatments.
Table 6: Multivariate Cox regression analyses for the factors associated with overall survival
OS
Variables HR 95% CI p-value
Initial clinical stage 3.597 1.037–12.480 0.044
ER 3.329 0.296–37.454 0.330
bcl-2 3.027 0.557–16.437 0.200
Triple negative 1.847 0.492–6.935 0.364
Kaplan-Meier analyses of (A) relapse free and (B) overall survival according to triple negative and non-triple negative breast  cancer Figure 2
Kaplan-Meier analyses of (A) relapse free and (B) overall survival according to triple negative and non-triple negative breast 
cancer.BMC Cancer 2007, 7:203 http://www.biomedcentral.com/1471-2407/7/203
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